Activity Summary:
These educational archived presentations will focus on issues related to HCV elimination among Appalachian community care providers. Topics discussed include approaches to identify patients at high risk, HCV screening and management strategies for persons who inject drugs and incarcerated persons, and gaps in the HCV care continuum and key tools that community healthcare professionals can use to achieve elimination goals within a clinical practice.

Dr. Sally Hodder and Dr. Alice Thornton will lead each of the 1-hour presentations along with a community expert in the each of the Appalachian regions.

Activity Summary:
We are pleased to have recently held the first virtual Optimal Management of HIV Disease & Hepatitis conference. This virtual conference was held in lieu of our typical in-person conference due to COVID-19. Despite this change, 15 leading clinicians and researchers in HIV and hepatitis medicine presented an array of topics covering HIV disease, hepatitis, HIV-hepatitis coinfection, and COVID-19. These presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These certified CME/CE enduring video archives of OPMAN XXVIII provide access to each day of the conference, including clinical presentations, interactive case discussions, and panel discussions addressing audience and faculty questions. CME/CE credit is provided separately by section so you can participate in only those sections of interest to you. We hope you enjoy this activity.

Activity Summary:
The Simply Speaking Hepatitis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

The national strategy for the elimination of HCV in the United States calls for a 90% reduction in the incidence of HCV and having 90% of those with HCV being treated. Scaling up HCV treatment in persons who inject drugs (PWIDs) and persons who are incarcerated is necessary to achieve HCV elimination targets.

These slides will review important issues for PWIDs and the incarcerated with HCV, including epidemiologic trends, prevention strategies, and AASLD recommendations for contemporary HCV management approaches/challenges and harm-reduction approaches.

Activity Summary:
The Simply Speaking Hepatitis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Critical to achieving the elimination of HCV infection is identifying HIV-infected persons with improved screening and surveillance approaches and linking them to HCV care and treatment. These steps will reduce the incidence of HCV, cirrhosis, HCC, liver-related deaths, and retransmission of HCV. These slides will review the changing epidemiology/ demographics of HCV infection and burden of disease and discusses screening and linkage-to-care approaches important to achieving the elimination of HCV infection in the United States.

Activity Summary:
The Simply Speaking Hepatitis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Achieving a sustained virologic response (SVR) is expected to benefit nearly all persons with chronic HCV infection. Despite the recommendation for treatment of nearly all patients with HCV infection, it remains critical for clinicians to understand patient- and disease-related factors that place individuals at risk for HCV-related complications as well as for HCV transmission. It is important that clinicians recognize the unique dimensions of HCV disease and its natural history in these populations when considering HCV regimen options. These slides will use a case-based format to review the contemporary management of HCV infection before and after the cure in treatment-naïve and experienced patients with various comorbidities.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Non-alcoholic steatohepatitis (NASH) is a growing cause of cirrhosis, HCC, and liver transplantation. Treatment options for NASH remain limited. Management of NASH typically focuses on treating liver disease and associated metabolic comorbidities. However, no single treatment approach has proved universally applicable to the general population with NASH. Given the biologic complexity of NASH and its heterogeneity, it is unlikely that only one drug will be sufficient to treat all patients.

These educational Conversations in NASH will discuss the current and future burden of disease due to NASH, the potential noninvasive testing modalities for diagnosis and staging of disease, important management considerations, and the latest clinical data for the treatment of NASH.

Activity Summary:
The Simply Speaking Hepatitis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Recent advances in HCV treatment offer an unprecedented opportunity to eliminate HCV. Scaling up HCV treatment in persons who inject drugs (PWIDs) is necessary to positively impact the HCV epidemic in the US and globally. In addition, to eliminate HCV, there is a need to engage the criminal justice system by increasing routine screening and improving access to direct-acting antiviral agents to persons who are imprisoned. These slides will address important issues for PWIDs and the incarcerated with HCV, including epidemiologic trends, prevention strategies, and AASLD recommendations for contemporary HCV management approaches/challenges and harm reduction approaches.

Updated information is noted on the slide in the upper right-hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Simply Speaking Hepatitis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Critical to achieving the elimination of HCV infection is identifying infected persons with improved screening and surveillance approaches and linking them to HCV care and treatment. These steps will reduce the incidence of HCV, cirrhosis, HCC, liver-related deaths, and retransmission of HCV. These slides review the changing epidemiology/demographics of HCV infection, burden of disease, and discusses screening and linkage-to-care approaches important to achieving the elimination of HCV infection in the United States.

Updated information is noted on the slide in the upper right-hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Simply Speaking Hepatitis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Chronic HCV infection affects over 3 million Americans and is a leading cause of liver failure, cirrhosis, and liver cancer. There are an increasing number of young patients and patients with milder disease than described in previous years. Understanding nuances of HCV disease in different patient populations require clinicians to become continually educated on the safe and appropriate use of direct-acting antiviral agents in clinical practice. These slides use a case-based format to discuss the contemporary management of HCV infection before and after the cure in treatment-naïve and experienced patients with various comorbidities.

Updated information is noted on the slide in the upper right-hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The national strategy for the elimination of HCV in the United States calls for a 90% reduction incidence of HCV and having 90% of those with HCV being treated. Significant strides have been achieved in simplifying HCV treatment regimens and improving SVR rates. Despite these advances, there are a number of challenging scenarios in HCV that require clinicians to become continually educated on the state-of-the-art approach to HCV management as well as safe and appropriate use of DAA regimens.

These Conversations in HCV will discuss the progress and barriers to achieving HCV elimination, challenging management issues in special patient populations, and strategies for HCV/HIV and HCV/HBV coinfection.

Activity Summary:
Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care. This activity will explain how recent study results in HCV apply to clinical practice, discuss significant developments and strategies in HCV therapy, discuss results from key clinical studies on new antiviral therapy, and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of hepatitis C through a series of daily, ‘what you need to know in 5-minutes’ videos each day from AASLD 2018.

Activity Summary:
Thrombocytopenia is a common manifestation among patients with chronic liver disease. In the setting of advanced liver disease, thrombocytopenia may negatively impact patient care by interfering with diagnostic and therapeutic procedures. The development of thrombopoietin agonists has the potential to provide clinicians with new options to improve patient care. However, current guidelines provide limited guidance on the optimal approach to increase platelet counts in patients with chronic liver disease.

These educational Mini Modules will outline the pathophysiologic mechanisms, platelet threshold levels, and other factors that impact the decision to initiate treatment for thrombocytopenia. In addition, the benefits and limitations of current and emerging therapeutic options will be discussed.

Activity Summary:
Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care. This activity will explain how recent study results in HCV apply to clinical practice, discuss significant developments and strategies in HCV therapy, discuss results from key clinical studies on new antiviral therapy, and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of hepatitis C through a series of daily, ‘what you need to know in 5-minutes’ videos each day from the 53rd Annual Congress of the European Association for the Study of the Liver (EASL).

Activity Summary:
We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXVI (OPMAN). The conference took place March 23-25, 2018, in Orlando, Florida with 15 of the leading clinicians and researchers in HIV and hepatitis medicine presenting an array of topics covering HIV disease, hepatitis and HIV-hepatitis coinfection. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These certified CME/CE enduring video archives of OPMAN XXVI provide access to each day of the conference, including the clinical presentations, interactive case discussions and panel discussions addressing audience and faculty questions. CME/CE credit is provided separately by section so you can participate in only those sections of interest to you. We hope you enjoy this activity.

Activity Summary:
New pan-genotypic regimens continue to transform HCV management with more potent, more convenient, and safer regimens. These rapid changes require clinicians to become continually educated on the state-of-the-art approach to HCV management as well as safe and appropriate use of these newer regimens.

These Conversations in HCV will discuss the use of 8- or 12-week HCV regimens in treatment-naïve patients, HCV management issue in contemporary difficult-to-cure patients, and considerations in the setting of renal disease, HCC, and transplantation.

Activity Summary:
This certified CME/CNE Interactive Case Review will address epidemiologic trends using a case-based approach to discuss optimal HCV therapy options and management approaches/challenges for patients with these various conditions.

Dr. Brown and Dr. Sulkowksi will discuss screening, prevention and treatment of hepatitis C virus (HCV) infection among special patient populations. Approaches necessary to achieve successful treatment of HCV in patients with HBV coinfection, HIV coinfection, advanced liver disease, and concomitant renal disease will be reviewed. Each Interactive Case has thought-provoking questions from the faculty built into the end giving users the opportunity to test their understanding of the material presented.

Activity Summary:
Management of the HIV/hepatitis-coinfected patient requires a multidisciplinary approach tailored to the treatment needs of HIV, hepatitis infection, or both and the potential ability of the patient to adhere to and tolerate treatment.

These educational mini modules will describe the epidemiology and significance of liver disease and hepatitis in HIV, explain the impact of ART on liver disease, and discuss current approaches to treating HCV and HBV infection in patients with HIV disease.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Activity Summary:
Advances in hepatitis C research unfold rapidly. Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care.

These educational Mini Modules from the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2017 will explain how recent study results in HCV apply to clinical practice and discuss significant developments and strategies in HCV therapy and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

Activity Summary:
Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care. This activity will explain how recent study results in HCV apply to clinical practice, discuss significant developments and strategies in HCV therapy, discuss results from key clinical studies on new antiviral therapy, and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of hepatitis C through a series of daily, ‘what you need to know in 5-minutes’ videos each day from AASLD 2017.

Activity Summary:
Chronic infection with hepatitis C virus (HCV) is a serious health issue for the nearly 200 million infected persons worldwide. Achievement of a SVR may be associated with improved long-term clinical outcomes, including increased survival. Because of the intricacies and challenges associated with monitoring disease status and HCV treatment, healthcare providers often turn to guideline recommendations and best practices when tailoring therapy to achieve the best results for the individual patient.

These Mini Modules will review the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) recommendations on the use of HCV regimens for HCV genotypes 1 through 6, including treatment eligibility and when to start therapy.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease.

No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options. These educational Mini Modules will review the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Activity Summary:
Chronic hepatitis B virus (HBV) infection is a prevalent medical condition in the United States and leads to significant morbidity and mortality.

These educational Mini Modules review the burden of chronic HBV infection, describes the various serum markers of HBV infection and their clinical importance, and reviews evidence-based and AASLD treatment recommendations for chronic HBV infection. Furthermore, the results from recent clinical trials of preferred HBV antiviral agents are discussed.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.